Searched for
CDMO REVENUE
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Crude awakening: Chemical companies face margin pressure as oil-linked costs surge amid geopolitical tensionsRising crude oil prices are pressuring chemical sector margins due to increased feedstock and energy costs. Despite this, the Nifty Chemica...
- Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defenc...
- Cenexi recovery, new product launches and capacity additions power Gland Pharma outlookGland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving p...
- Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividendShares of Gland Pharma rallied on Monday after the company reported a 97% YoY surge in Q4 profit and strong revenue growth, driven by its C...
- Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4Cohance Lifesciences shares dropped significantly after reporting an 84% year-on-year decline in March-quarter net profit. Jefferies downgr...
- Mayuresh Joshi's top picks: Chemicals the dark horse, underweight on ITIndian markets delivered strong earnings, but opportunities vary. Autos show stable demand with input cost risks. Chemicals are a potential...
- Laurus Labs Q4 Results: Cons PAT increased 19% to Rs 279 crore, revenue rises 5%Laurus Labs reported a 19% year-on-year jump in net profit to Rs 279 crore for the March quarter, with revenue rising 5% to Rs 1,812 crore....
- Nandini Piramal warns prolonged West Asia war may raise input costsGeopolitical tensions in West Asia are manageable now. However, a prolonged US-Israel war against Iran could raise costs for petrochemical-...
- Infosys Q4 profit spikes; Flipkart mulls separate app for MinutesInfosys closed FY26 with strong numbers aided by a pickup in demand from its banking, energy and communication segments. This and more in...
- Time to buy? Sunny Agrawal finds best picks across banking, pharma, capital markets & infrastructureIndian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...
- Capacity expansion, new launches to support Navin Fluorine's growthNavin Fluorine International's shares have seen a significant rise, fueled by newly commissioned capacities and a robust specialty chemical...
- Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and ...
- Piramal Pharma Q2 Results: Co posts net profit of Rs 23 croreThe contract research and manufacturing services (CDMO) revenues rose 24% YoY to Rs 1324 crore led by order inflow momentum, especially for...
- Piramal Pharma targets to double revenue in 5 yearsPiramal Pharma aims to achieve $2 billion in annual revenue with a 25% operating margin by fiscal 2030, driven by its CDMO business. The co...
- Merger effect! Suven Pharma shares jump 15% in 2 daysAfter the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every...
- Fundamental Radar: Why does Piramal Pharma stock deserve a re-rating? Sandeep Raina explainsThe company witnessed multiple challenges related to macroeconomic factors during and after COVID-19, high attrition at European manufactur...
- CRAMS could be new wealth creators in pharma spaceMore and more pharma cos are finding it profitable to outsource all aspects from R&D to commercialisation to trusted partners in low-cost c...
Load More
